Helicos Hires Investment Bank to Advise on 'Strategic Alternatives,' Clarifies Instrument Placements

As of mid-August, the company, which has installed six instruments outside its premises, had $5 million in cash and cash equivalents. Recent discussions with potential strategic partners "have involved parties inside and outside the genetic sequencing space."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.